Literature DB >> 19073821

Diagnosis, pathogenesis, treatment, and prognosis of hereditary fibrinogen A alpha-chain amyloidosis.

Julian D Gillmore1, Helen J Lachmann, Dorota Rowczenio, Janet A Gilbertson, Cai-Hong Zeng, Zhi-Hong Liu, Lei-Shi Li, Ashutosh Wechalekar, Philip N Hawkins.   

Abstract

Mutations in the fibrinogen A alpha-chain gene are the most common cause of hereditary renal amyloidosis in the United Kingdom. Previous reports of fibrinogen A alpha-chain amyloidosis have been in isolated kindreds, usually in the context of a novel amyloidogenic mutation. Here, we describe 71 patients with fibrinogen amyloidosis, who were prospectively studied at the UK National Amyloidosis Centre. Median age at presentation was 58 yr, and renal involvement led to diagnosis in all cases. Even after a median follow-up of 4 yr, clinically significant extra-renal disease was rare. Renal histology was characteristic: striking glomerular enlargement with almost complete obliteration of the normal architecture by amyloid deposition and little or no vascular or interstitial amyloid. We discovered four amyloidogenic mutations in fibrinogen (P552H, E540V, T538K, and T525fs). A family history of renal disease was frequently absent. Median time from presentation to ESRD was 4.6 yr, and the estimated median patient survival from presentation was 15.2 yr. Among 44 patients who reached ESRD, median survival was 9.3 yr. Twelve renal transplants survived for a median of 6.0 (0-12.2) yr. Seven grafts had failed after median follow up from transplantation of 5.8 yr, including three from recurrent amyloid after 5.8, 6.0, and 7.4 yr; three grafts failed immediately for surgical reasons and one failed from transplant glomerulopathy after 5.8 yr with no histological evidence of amyloid. At censor, the longest surviving graft was 12.2 yr. In summary, fibrinogen amyloidosis is predominantly a renal disease characterized by variable penetrance, distinctive histological appearance, proteinuria, and progressive renal impairment. Survival is markedly better than observed with systemic AL amyloidosis, and outcomes with renal replacement therapy are comparable to those for age-matched individuals with nondiabetic renal disease.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19073821      PMCID: PMC2637055          DOI: 10.1681/ASN.2008060614

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  29 in total

1.  A novel apolipoprotein A-1 variant, Arg173Pro, associated with cardiac and cutaneous amyloidosis.

Authors:  K Hamidi Asl; J J Liepnieks; M Nakamura; F Parker; M D Benson
Journal:  Biochem Biophys Res Commun       Date:  1999-04-13       Impact factor: 3.575

2.  Curative hepatorenal transplantation in systemic amyloidosis caused by the Glu526Val fibrinogen alpha-chain variant in an English family.

Authors:  J D Gillmore; D R Booth; M Rela; N D Heaton; V Rahman; A J Stangou; M B Pepys; P N Hawkins
Journal:  QJM       Date:  2000-05

3.  Apolipoprotein AI and transthyretin as components of amyloid fibrils in a kindred with apoAI Leu178His amyloidosis.

Authors:  M M de Sousa; C Vital; D Ostler; R Fernandes; J Pouget-Abadie; D Carles; M J Saraiva
Journal:  Am J Pathol       Date:  2000-06       Impact factor: 4.307

4.  A new human hereditary amyloidosis: the result of a stop-codon mutation in the apolipoprotein AII gene.

Authors:  M D Benson; J J Liepnieks; M Yazaki; T Yamashita; K Hamidi Asl; B Guenther; B Kluve-Beckerman
Journal:  Genomics       Date:  2001-03-15       Impact factor: 5.736

5.  Hereditary amyloidosis in early childhood associated with a novel insertion-deletion (indel) in the fibrinogen Aalpha chain gene.

Authors:  Hee Gyung Kang; Alison Bybee; Il Soo Ha; Moon Soo Park; Janet A Gilbertson; Hae Il Cheong; Yong Choi; Philip N Hawkins
Journal:  Kidney Int       Date:  2005-11       Impact factor: 10.612

Review 6.  Perspectives in treatment of AL amyloidosis.

Authors:  Ashutosh D Wechalekar; Philip N Hawkins; Julian D Gillmore
Journal:  Br J Haematol       Date:  2007-12-19       Impact factor: 6.998

7.  Human plasma fibrinogen is synthesized in the liver.

Authors:  Glenys A Tennent; Stephen O Brennan; Arie J Stangou; John O'Grady; Philip N Hawkins; Mark B Pepys
Journal:  Blood       Date:  2006-11-02       Impact factor: 22.113

8.  Organ transplantation in hereditary apolipoprotein AI amyloidosis.

Authors:  J D Gillmore; A J Stangou; H J Lachmann; H J Goodman; A D Wechalekar; J Acheson; G A Tennent; A Bybee; J Gilbertson; D Rowczenio; J O'Grady; N D Heaton; M B Pepys; P N Hawkins
Journal:  Am J Transplant       Date:  2006-08-21       Impact factor: 8.086

9.  The new apolipoprotein A-I variant leu(174) --> Ser causes hereditary cardiac amyloidosis, and the amyloid fibrils are constituted by the 93-residue N-terminal polypeptide.

Authors:  L Obici; V Bellotti; P Mangione; M Stoppini; E Arbustini; L Verga; I Zorzoli; E Anesi; G Zanotti; C Campana; M Viganò; G Merlini
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

10.  Natural history and outcome in systemic AA amyloidosis.

Authors:  Helen J Lachmann; Hugh J B Goodman; Janet A Gilbertson; J Ruth Gallimore; Caroline A Sabin; Julian D Gillmore; Philip N Hawkins
Journal:  N Engl J Med       Date:  2007-06-07       Impact factor: 91.245

View more
  31 in total

1.  Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis.

Authors:  Sanjeev Sethi; Jason D Theis; Nelson Leung; Angela Dispenzieri; Samih H Nasr; Mary E Fidler; Lynn D Cornell; Jeffrey D Gamez; Julie A Vrana; Ahmet Dogan
Journal:  Clin J Am Soc Nephrol       Date:  2010-09-28       Impact factor: 8.237

2.  VLITL is a major cross-β-sheet signal for fibrinogen Aα-chain frameshift variants.

Authors:  Cyrille Garnier; Fatma Briki; Brigitte Nedelec; Patrick Le Pogamp; Ahmet Dogan; Nathalie Rioux-Leclercq; Renan Goude; Caroline Beugnet; Laurent Martin; Marc Delpech; Frank Bridoux; Gilles Grateau; Jean Doucet; Philippe Derreumaux; Sophie Valleix
Journal:  Blood       Date:  2017-10-31       Impact factor: 22.113

Review 3.  Fibrinogen alpha amyloidosis: insights from proteomics.

Authors:  Jessica Chapman; Ahmet Dogan
Journal:  Expert Rev Proteomics       Date:  2019-08-28       Impact factor: 3.940

Review 4.  Pathology and diagnosis of renal non-AL amyloidosis.

Authors:  Sanjeev Sethi; Jason D Theis
Journal:  J Nephrol       Date:  2017-08-21       Impact factor: 3.902

5.  Amyloidogenicity and clinical phenotype associated with five novel mutations in apolipoprotein A-I.

Authors:  Dorota Rowczenio; Ahmet Dogan; Jason D Theis; Julie A Vrana; Helen J Lachmann; Ashutosh D Wechalekar; Janet A Gilbertson; Toby Hunt; Simon D J Gibbs; Prayman T Sattianayagam; Jenny H Pinney; Philip N Hawkins; Julian D Gillmore
Journal:  Am J Pathol       Date:  2011-08-05       Impact factor: 4.307

Review 6.  Endoplasmic reticulum quality control and systemic amyloid disease: Impacting protein stability from the inside out.

Authors:  John J Chen; Joseph C Genereux; R Luke Wiseman
Journal:  IUBMB Life       Date:  2015-05-26       Impact factor: 3.885

Review 7.  Currents concepts on the immunopathology of amyloidosis.

Authors:  Anupama Bhat; Carlo Selmi; Stanley M Naguwa; Gurtej S Cheema; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2010-04       Impact factor: 8.667

8.  Renal amyloidosis: origin and clinicopathologic correlations of 474 recent cases.

Authors:  Samar M Said; Sanjeev Sethi; Anthony M Valeri; Nelson Leung; Lynn D Cornell; Mary E Fidler; Loren Herrera Hernandez; Julie A Vrana; Jason D Theis; Patrick S Quint; Ahmet Dogan; Samih H Nasr
Journal:  Clin J Am Soc Nephrol       Date:  2013-05-23       Impact factor: 8.237

Review 9.  Pathophysiology and treatment of systemic amyloidosis.

Authors:  Julian D Gillmore; Philip N Hawkins
Journal:  Nat Rev Nephrol       Date:  2013-08-27       Impact factor: 28.314

10.  Laser microdissection and mass spectrometry-based proteomics aids the diagnosis and typing of renal amyloidosis.

Authors:  Sanjeev Sethi; Julie A Vrana; Jason D Theis; Nelson Leung; Anjali Sethi; Samih H Nasr; Fernando C Fervenza; Lynn D Cornell; Mary E Fidler; Ahmet Dogan
Journal:  Kidney Int       Date:  2012-04-11       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.